Federal contract award
75F40120C00179
BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $1.4M |
| Current contract value | $1.4M |
| Potential contract value / ceiling | $1.4M |
| Start date | Sep 25, 2020 |
| Current end date | Jun 30, 2024 |
| Potential end date | Jun 30, 2024 |
| Latest award activity | Jul 12, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 12, 2026 | P00006 | $-169.4K | QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
| Mar 5, 2024 | P00005 | $-55.2K | QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
| Jul 20, 2022 | P00004 | $0 | QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
| Apr 4, 2022 | P00003 | $0 | EO14042 BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
| Nov 15, 2021 | P00002 | $0 | EO14042 BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
| Feb 8, 2021 | P00001 | $571.9K | BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
| Sep 25, 2020 | 0 | $1.1M | BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Christine Russman | Contact | Christine.Russman@fda.hhs.gov 3017967841 | Source | Jan 17, 2020 |
| Richard Robinson | Contact | Richard.Robinson@fda.hhs.gov 301-796-6508 | Source | Jan 17, 2020 |
| Christine Russman | Contact | Christine.Russman@fda.hhs.gov 3017967841 | Source | Jan 17, 2020 |
| Richard Robinson | Contact | Richard.Robinson@fda.hhs.gov 301-796-6508 | Source | Jan 17, 2020 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.